CHICAGO -- A widely used chemotherapy regimen for early breast cancer encountered a "practice changing failure" in a retrospective survival analysis, reported here at the American Society of Clinical Oncology meeting, involving several clinical trials. In an exclusive 番茄社区app video interview, , of Memorial Sloan Kettering Cancer Center in New York City, explains why breast cancer specialists might have a hard time justifying continued use of taxane-cyclophosphamide chemotherapy regimens for early breast cancer.
![author['full_name']](https://clf1.medpagetoday.com/media/images/author/charlesBankhead_188.jpg)